News
-
Chiesi Group announced that it will spend €430 million to construct a new manufacturing facility on a site that it has acquired in Nerviano, Italy. The site will produce metered dose inhalers with low global warming… Read more . . .
-
Savara announced that it has completed its BLA submission for Molbreevi molgramostim inhalation solution for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). The company had announced the initiation of the rolling submission in December 2024.… Read more . . .
-
Irish nebulization specialist Aerogen has announced the official opening of its India headquarters in New Delhi. According to Aerogen, the New Delhi office includes a library and recreation space in addition to offices for sales, marketing,… Read more . . .
-
Vast Therapeutics announced that its ALX1 inhalation solution for the treatment of lung infections has received Qualified Infectious Disease Product designation from the FDA. The company describes ALX1 as a nitric oxide pro-drug, and the… Read more . . .
-
According to ReCode Therapeutics, the FDA has granted orphan drug designation to the company’s RCT2100 inhaled mRNA therapy for the treatment of cystic fibrosis in patients who do not benefit from CFTR modulators. In February… Read more . . .
-
French biotech Lovaltech announced that the Agence nationale de sécurité du médicament (ANSM) and the Comité de Protection des Personnes (CPP) have authorized the company’s planned MUCOBOOST Phase 1 trial of LVT-001 nasal vaccine against… Read more . . .
-
Orbia Fluor & Energy Materials (formerly Koura) has announced the appointments of a new General Manager, Global Commercial Director, UK Operations Director, and Technical Manager for its Pharma Business Unit, which includes Zephex brand MDI… Read more . . .
-
According to Emergent BioSolutions, Health Canada has approved Hikma Pharmaceuticals’ Kloxxado naloxone nasal spray 8 mg for the treatment of opioid overdose. In January 2025, Emergent announced that it was acquiring US and Canadian rights to… Read more . . .
-
US-based Paratek Pharmaceuticals will acquire all outstanding shares of intranasal drug developer Optinose in a deal worth up to $330 million, the companies said. According to the announcement, both companies’ boards have approved the deal,… Read more . . .
-
Cyrano Therapeutics has acquired an exclusive license to use Resyca’s soft mist nasal spray technology for delivery of CYR-064 intranasal theophylline for the treatment of post-viral hyposmia. According to the announcement, the Phase 2 FLAVOR… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden